Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 206 pharmacokinetic similarity study versus Opdivo in resected stage III/IV melanoma
NL-OMON59869Phase 1Completed
- Sponsor
- Amgen
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1 trial of ABP 206 and nivolumab in melanoma (2 arms), sponsored by Amgen. Started Mar 2024; status: completed.
02
Drugs
ABP 206nivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON59869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59869.